O23 Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomesChristopher J Edwards, Soyi Liu Leage, Burkhard Möller et al.|Lara D. Veeken|2020Cited by 2